Approved Drugs - Repurposing
Cutting edge small molecule reagents targeting key proteins and mechanisms of coronavirus infection.
All compounds - Approved drugs: in clinical trials - Approved drugs: repurposing - Other compounds
| Compound | Primary Activity(s) |
|---|---|
| A77 1726 | Immunosuppressant; DHODH inhibitor |
| Auranofin | Thioredoxin reductase inhibitor, leading to unfolded protein response (UPR) |
| Boceprevir | Protease inhibitor: HCV NS3 protease |
| Captopril | Protease inhibitor: ACE |
| Carfilzomib | Proteasome inhibitor |
| Dabrafenib (GSK2118436) | Kinase inhibitor: B-Raf mutant; Autophagy modulator |
| Dasatinib | Kinase inhibitor: tyrosine kinases |
| Daunorubicin HCl | DNA damaging agent; Autophagy modulator |
| Entacapone | Methyltransferase (COMT) inhibitor |
| Everolimus | mTOR inhibitor; Autophagy modulator |
| FK-506 | FKBP inhibitor |
| Gemcitabine HCl | Nucleoside analog |
| Metformin HCl | Antidiabetic agent; Autophagy modulator |
| Miglustat HCl | α-glucosidase, glycosyltransferase inhibitor |
| Mycophenolic acid | Immunosuppressant |
| Nelfinavir mesylate | Protease inhibitor: HIV-1 protease; Autophagy modulator |
| Niclosamide | Kinase (STAT3) signaling inhibitor; Autophagy modulator |
| Nitazoxanide | Antiviral, antiparasitic |
| Palbociclib (PD0332991) | Kinase inhibitor: CDK4 / CDK6; Autophagy modulator |
| PKC-412 | Kinase inhibitor (pan specific) |
| Rapamycin | mTOR inhibitor; Autophagy modulator |
| Ribavirin | Antiviral agent |
| Sodium valproate | HDAC inhibitor |
| Tigecycline | Antibiotic |
| Tolcapone | Methyltransferase (COMT) inhibitor |
| Verapamil HCl | Ion channel antagonist |
Products
No products are currently available in this category.